Table of Contents
ISRN Nephrology
Volume 2013, Article ID 159760, 11 pages
http://dx.doi.org/10.5402/2013/159760
Review Article

Hepatitis C Virus Infection and Dialysis: 2012 Update

Division of Nephrology and Dialysis, Maggiore Hospital and IRCCS Foundation, Padiglione Croff, Via Commenda 15, 20122 Milan, Italy

Received 23 October 2012; Accepted 14 November 2012

Academic Editors: R. Bhimma, P.-Y. Durand, and C. Escobar

Copyright © 2013 Fabrizio Fabrizi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Fabrizi, V. Dixit, P. Messa, and P. Martin, “Hepatitis C-related liver disease in dialysis patients,” Contributions to Nephrology, vol. 176, pp. 42–53, 2012. View at Google Scholar
  2. N. Perico, D. Cattaneo, B. Bikbov, and G. Remuzzi, “Hepatitis C infection and chronic renal diseases,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 1, pp. 207–220, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Hanuka, E. Sikuler, D. Tovbin et al., “Hepatitis C virus infection in renal failure patients in the absence of anti-hepatitis C virus antibodies,” Journal of Viral Hepatitis, vol. 9, no. 2, pp. 141–145, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. Kidney Disease: Improving Global Outcomes, “KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease,” Kidney International, vol. 73, supplement 109, pp. S1–S99, 2008. View at Google Scholar
  5. P. M. Schneeberger, I. Keur, A. M. van Loon et al., “The prevalence and incidence of hepatitis C virus infections among dialysis patients in The Netherlands: a nationwide prospective study,” Journal of Infectious Diseases, vol. 182, no. 5, pp. 1291–1299, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Hinrichsen, G. Leimenstoll, G. Stegen, H. Schrader, U. R. Fölsch, and W. E. Schmidt, “Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients,” Gut, vol. 51, no. 3, pp. 429–433, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Sauné, N. Kamar, M. Miédougé et al., “Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey,” Nephrology Dialysis Transplantation, vol. 26, no. 7, pp. 2309–2316, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Petrosillo, P. Gilli, D. Serraino et al., “Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis,” American Journal of Kidney Diseases, vol. 37, no. 5, pp. 1004–1010, 2001. View at Google Scholar · View at Scopus
  9. Z. Hruby, J. Sliwinski, I. Molin et al., “High prevalence of antibodies to hepatitis C virus in three haemodialysis centres in south-western Poland,” Nephrology Dialysis Transplantation, vol. 8, no. 8, pp. 740–743, 1993. View at Google Scholar · View at Scopus
  10. P. Luengrojanakul, K. Vareesangthip, T. Chainuvati et al., “Hepatitis C virus infection in patients with chronic liver disease or chronic renal failure and blood donors in Thailand,” Journal of Medical Virology, vol. 44, no. 3, pp. 287–292, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Huraib, R. Al-Rashed, A. Aldrees, M. Aljefry, M. Arif, and F. A. Al-Faleh, “High prevalence of and risk factors for hepatitis C in haemodialysis patients in Saudi Arabia: a need for new dialysis strategies,” Nephrology Dialysis Transplantation, vol. 10, no. 4, pp. 470–474, 1995. View at Google Scholar · View at Scopus
  12. M. J. D. Cassidy, D. Jankelson, M. Becker, T. Dunne, G. Walzl, and M. R. Moosa, “The prevalence of antibodies to hepatitis C virus at two haemodialysis units in South Africa,” South African Medical Journal, vol. 85, no. 10, pp. 996–998, 1995. View at Google Scholar · View at Scopus
  13. M. Voiculescu, L. Iliescu, C. Ionescu et al., “A cross-sectional epidemiological study of HBV, HCV, HDV and HEV prevalence in the SubCarpathian and South-Eastern regions of Romania,” Journal of Gastrointestinal and Liver Diseases, vol. 19, no. 1, pp. 43–48, 2010. View at Google Scholar · View at Scopus
  14. M. A. M. Santos and F. J. D. Souto, “Infection by the hepatitis C virus in chronic renal failure patients undergoing hemodialysis in Mato Grosso state, central Brazil: a cohort study,” BMC Public Health, vol. 7, article 32, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. D. W. Johnson, H. Dent, Q. Yao et al., “Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data,” Nephrology Dialysis Transplantation, vol. 24, no. 5, pp. 1598–1603, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. R. B. Fissell, J. L. Bragg-Gresham, J. D. Woods et al., “Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS,” Kidney International, vol. 65, no. 6, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Jadoul, J. L. Poignet, C. Geddes et al., “The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study,” Nephrology Dialysis Transplantation, vol. 19, no. 4, pp. 904–909, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Espinosa, A. Martín-Malo, R. Ojeda et al., “Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes and consequences,” American Journal of Kidney Diseases, vol. 43, no. 4, pp. 685–689, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Barril and J. A. Traver, “Decrease in the hepatitis C virus (HCV) prevalence in hemodialysis patients in Spain: effect of time, initiating HCV prevalence studies and adoption of isolation measures,” Antiviral Research, vol. 60, no. 2, pp. 129–134, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Finelli, J. T. Miller, J. I. Tokars, M. J. Alter, and M. J. Arduino, “National surveillance of dialysis-associated diseases in the United States, 2002,” Seminars in Dialysis, vol. 18, no. 1, pp. 52–61, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Fabrizi, P. Martin, V. Dixit et al., “Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey,” Nephron, vol. 80, no. 4, pp. 428–433, 1998. View at Google Scholar · View at Scopus
  22. F. Fabrizi, A. F. De Vecchi, A. R. Qureshi et al., “Gamma glutamyltranspeptidase activity and viral hepatitis in dialysis population,” International Journal of Artificial Organs, vol. 30, no. 1, pp. 6–15, 2007. View at Google Scholar · View at Scopus
  23. K. Kalantar-Zadeh, R. D. Kilpatrick, C. J. McAllister et al., “Hepatitis C virus and death risk in hemodialysis patients,” Journal of the American Society of Nephrology, vol. 18, no. 5, pp. 1584–1593, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Kalantar-Zadeh, C. J. McAllister, and L. G. Miller, “Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study,” Nephrology Dialysis Transplantation, vol. 20, no. 8, pp. 1662–1669, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. V. Goral, M. Simsek, and N. Mete, “Hepatic osteodystrophy and liver cirrhosis,” World Journal of Gastroenterology, vol. 16, no. 13, pp. 1639–1643, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Marcelli, D. Stannard, F. Conte, P. J. Held, F. Locatelli, and F. K. Port, “ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States,” Kidney International, vol. 50, no. 3, pp. 1013–1018, 1996. View at Google Scholar · View at Scopus
  27. B. J. G. Pereira, S. N. Natov, B. A. Bouthot et al., “Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease,” Kidney International, vol. 53, no. 5, pp. 1374–1381, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. C. O. Stehman-Breen, S. Emerson, D. Gretch, and R. J. Johnson, “Risk of death among chronic dialysis patients infected with hepatitis C virus,” American Journal of Kidney Diseases, vol. 32, no. 4, pp. 629–634, 1998. View at Google Scholar · View at Scopus
  29. E. Nakayama, T. Akiba, F. Marumo, and C. Sato, “Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy,” Journal of the American Society of Nephrology, vol. 11, no. 10, pp. 1896–1902, 2000. View at Google Scholar · View at Scopus
  30. M. Espinosa, A. Martin-Malo, M. A. A. De Lara, and P. Aljama, “Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 16, no. 8, pp. 1669–1674, 2001. View at Google Scholar · View at Scopus
  31. M. Espinosa, A. Martin-Malo, M. A. Alvarez de Lara, R. Gonzalez, M. Rodriguez, and P. Aljama, “Natural history of acute HCV infection in hemodialysis patients,” Clinical Nephrology, vol. 58, no. 2, pp. 143–150, 2002. View at Google Scholar · View at Scopus
  32. A. Di Napoli, P. Pezzotti, D. Di Lallo, N. Petrosillo, C. Trivelloni, and S. Di Giulio, “Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian Region,” American Journal of Kidney Diseases, vol. 48, no. 4, pp. 629–637, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Dattolo, M. Lombardi, G. Ferro, S. Michelassi, T. Cerrai, and F. Pizzarelli, “Natural history of HCV infection and risk of death in a cohort of patients on long-term hemodialysis,” Giornale Italiano di Nefrologia, vol. 23, no. 6, pp. 585–590, 2006. View at Google Scholar · View at Scopus
  34. K. Kalantar-Zadeh, R. D. Kilpatrick, C. J. McAllister et al., “Hepatitis C virus and death risk in hemodialysis patients,” Journal of the American Society of Nephrology, vol. 18, no. 5, pp. 1584–1593, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. S. M. Wang, J. H. Liu, C. Y. Chou, C. C. Huang, C. M. Shih, and W. Chen, “Mortality in hepatitis C-positive patients treated with peritoneal dialysis,” Peritoneal Dialysis International, vol. 28, no. 2, pp. 183–187, 2008. View at Google Scholar · View at Scopus
  36. D. Santoro, G. Mazzaglia, V. Savica, M. L. Vecchi, and G. Bellinghieri, “Hepatitis status and mortality in hemodialysis population,” Renal Failure, vol. 31, no. 1, pp. 6–12, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. D. W. Johnson, H. Dent, Q. Yao et al., “Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data,” Nephrology Dialysis Transplantation, vol. 24, no. 5, pp. 1598–1603, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. D. R. Scott, J. K. W. Wong, T. S. Spicer et al., “Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand,” Transplantation, vol. 90, no. 11, pp. 1165–1171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Ohsawa, K. Kato, and K. Tanno, “Seropositivity with anti-HCV core antigen is independently associated with increased all-cause, cardiovascular, and liver disease-related mortality in haemodialysis patients,” Journal of Epidemiology, vol. 21, pp. 491–499, 2011. View at Google Scholar
  40. F. Fabrizi, V. Dixit, and P. Messa, “Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?” Journal of Viral Hepatitis, vol. 19, pp. 601–607, 2012. View at Google Scholar
  41. D. A. Goodkin, J. L. Bragg-Gresham, K. G. Koenig et al., “Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the dialysis outcomes and practice patterns study (DOPPS),” Journal of the American Society of Nephrology, vol. 14, no. 12, pp. 3270–3277, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Locatelli, D. Marcelli, F. Conte et al., “Cardiovascular disease in chronic renal failure: the challenge continues,” Nephrology Dialysis Transplantation, vol. 15, supplement 5, pp. 69–80, 2000. View at Google Scholar · View at Scopus
  43. D. Roth, J. J. Gaynor, K. R. Reddy et al., “Effect of kidney transplantation on outcomes among patients with hepatitis C,” Journal of the American Society of Nephrology, vol. 22, no. 6, pp. 1152–1160, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Oyake, T. Shimada, Y. Murakami et al., “Hepatitis C virus infection as a risk factor for increased aortic stiffness and cardiovascular events in dialysis patients,” Journal of Nephrology, vol. 21, no. 3, pp. 345–353, 2008. View at Google Scholar · View at Scopus
  45. B. Afsar, R. Elsurer, S. Sezer, and N. F. Ozdemir, “Quality of life in hemodialysis patients: hepatitis C virus infection makes sense,” International Urology and Nephrology, vol. 41, no. 4, pp. 1011–1019, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Akyuz, F. Besisik, B. Pinarbasi et al., “The quality of life in haemodialysis patients with chronic hepatitis C virus infection,” The Turkish Journal of Gastroenterology, vol. 20, pp. 2434–2246, 2009. View at Google Scholar
  47. F. G. Cosio, D. D. Sedmak, M. L. Henry et al., “The high prevalence of severe early posttransplant renal allograft pathology inhepatitis C positive recipients,” Transplantation, vol. 62, no. 8, pp. 1054–1059, 1996. View at Publisher · View at Google Scholar · View at Scopus
  48. J. M. Cruzado, M. Carrera, J. Torras, and J. M. Grinyó, “Hepatitis C virus infection and de novo glomerular lesions in renal allografts,” American Journal of Transplantation, vol. 1, no. 2, pp. 171–178, 2001. View at Google Scholar · View at Scopus
  49. J. M. Morales, J. Pascual-Capdevila, J. M. Campistol et al., “Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients,” Transplantation, vol. 63, no. 11, pp. 1634–1639, 1997. View at Publisher · View at Google Scholar · View at Scopus
  50. B. H. Özdemir, F. N. Özdemir, S. Sezer, T. Çolak, and M. Haberal, “De novo glomerulonephritis in renal allografts with hepatitis C virus infection,” Transplantation Proceedings, vol. 38, no. 2, pp. 492–495, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Roth, R. Cirocco, K. Zucker et al., “De novo membranoproliferative glomerulonephritis in hepatitis C virus- infected renal allograft recipients,” Transplantation, vol. 59, no. 12, pp. 1676–1682, 1995. View at Google Scholar · View at Scopus
  52. F. Fabrizi, P. Martin, V. Dixit, S. Bunnapradist, F. Kanwal, and G. Dulai, “Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies,” American Journal of Transplantation, vol. 5, no. 10, pp. 2433–2440, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Wolffenbüttel, D. D. Poli, R. C. Manfro, and L. F. S. Gonçalves, “Cyclosporine pharmacokinetics in anti-HCV + patients,” Clinical Transplantation, vol. 18, no. 6, pp. 654–660, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. J. P. Forman, N. Tolkoff-Rubin, M. Pascual, and J. Lin, “Hepatitis C, acute humoral rejection, and renal allograft survival,” Journal of the American Society of Nephrology, vol. 15, no. 12, pp. 3249–3255, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. F. Moreso, M. Ibernon, M. Gomà et al., “Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss,” American Journal of Transplantation, vol. 6, no. 4, pp. 747–752, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. J. M. Cruzado, T. Casanovas-Taltavull, J. Torras, C. Baliellas, S. Gil-Vernet, and J. M. Grinyó, “Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance,” American Journal of Transplantation, vol. 3, no. 3, pp. 357–360, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Gürsoy, N. Güvener, R. Köksal et al., “Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients,” Transplantation Proceedings, vol. 32, no. 3, pp. 561–562, 2000. View at Publisher · View at Google Scholar · View at Scopus
  58. I. M. Mahmoud, M. A. Sobh, A. F. El-Habashi et al., “Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course,” Nephron, vol. 100, no. 4, pp. c133–c139, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. M. W. Fried, M. L. Shiffman, K. Rajender Reddy et al., “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection,” The New England Journal of Medicine, vol. 347, no. 13, pp. 975–982, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. M. P. Manns, J. G. McHutchison, S. C. Gordon et al., “Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial,” The Lancet, vol. 358, no. 9286, pp. 958–965, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. S. J. Hadziyannis, H. Sette, T. R. Morgan et al., “Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a Randomized study of treatment duration and ribavirin dose,” Annals of Internal Medicine, vol. 140, no. 5, pp. 346–I67, 2004. View at Google Scholar · View at Scopus
  62. P. Koenig, W. Vogel, F. Umlauft et al., “Interferon treatment for chronic hepatitis C virus infection in uremic patients,” Kidney International, vol. 45, no. 5, pp. 1507–1509, 1994. View at Google Scholar · View at Scopus
  63. S. Pol, V. Thiers, F. Carnot et al., “Efficacy and tolerance of α-2b interferon therapy on HCV infection of hemodialyzed patients,” Kidney International, vol. 47, no. 5, pp. 1412–1418, 1995. View at Google Scholar · View at Scopus
  64. M. Raptopoulou-Gigi, S. Spaia, A. Garifallos et al., “Interferon-α2b treatment of chronic hepatitis C in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 10, no. 10, pp. 1834–1837, 1995. View at Google Scholar · View at Scopus
  65. J. L. Fernández, P. Rendo, N. Del Pino et al., “A double-blind controlled trial of recombinant interferon-α2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels,” Journal of Viral Hepatitis, vol. 4, no. 2, pp. 113–119, 1997. View at Google Scholar · View at Scopus
  66. J. M. Campistol, N. Esforzado, J. Martínez et al., “Efficacy and tolerance of interferon-α2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment,” Nephrology Dialysis Transplantation, vol. 14, no. 11, pp. 2704–2709, 1999. View at Google Scholar · View at Scopus
  67. C. Hanrotel, O. Toupance, S. Lavaud et al., “Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C,” Nephron, vol. 88, no. 2, pp. 120–126, 2001. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Huraib, A. Iqbal, D. Tanimu, and A. Abdullah, “Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C,” American Journal of Nephrology, vol. 21, no. 6, pp. 435–440, 2001. View at Publisher · View at Google Scholar · View at Scopus
  69. T. Casanovas-Taltavull, C. Baliellas, C. Benasco et al., “Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation,” American Journal of Gastroenterology, vol. 96, no. 4, pp. 1170–1177, 2001. View at Publisher · View at Google Scholar · View at Scopus
  70. F. Degos, S. Pol, M. L. Chaix et al., “The tolerance and efficacy of interferon-α in haemodialysis patients with HCV infection: a multicentre, prospective study,” Nephrology Dialysis Transplantation, vol. 16, no. 5, pp. 1017–1023, 2001. View at Google Scholar · View at Scopus
  71. M. Espinosa, M. Rodriguez, A. Martin-Malo et al., “Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response,” Clinical Nephrology, vol. 55, no. 3, pp. 220–226, 2001. View at Google Scholar · View at Scopus
  72. I. Sporea, O. Golea, C. Ursu et al., “Effect of alpha 2b interferon treatment in hemodialyzed patients with chronic hepatitis C,” Romanian Journal of Gastroenterology, vol. 10, no. 4, pp. 285–288, 2001. View at Google Scholar · View at Scopus
  73. F. N. Ozdemir, A. Akcay, S. Sezer et al., “A six-year follow-up after interferon-alpha monotherapy for chronic hepatitis C infection in hemodialysis patients,” Renal Failure, vol. 26, no. 5, pp. 583–588, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. N. Kamar, O. Toupance, M. Buchler et al., “Evidence that clearance of hepatitis C virus RNA after α-interferon therapy in dialysis patients is sustained after renal transplantation,” Journal of the American Society of Nephrology, vol. 14, no. 8, pp. 2092–2098, 2003. View at Publisher · View at Google Scholar · View at Scopus
  75. I. M. Mahmoud, M. A. Sobh, A. F. El-Habashi et al., “Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course,” Nephron, vol. 100, no. 4, pp. c133–c139, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Rivera, M. A. Gentil, M. Sayago et al., “Treatment of hepatitis C virus with interferon in hemodialysis patients awaiting kidney transplant,” Transplantation Proceedings, vol. 37, no. 3, pp. 1424–1425, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. C. M. Rocha, R. M. Perez, A. P. Ferreira et al., “Efficacy and tolerance of interferon-α in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis,” Liver International, vol. 26, no. 3, pp. 305–310, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Buargub, S. El Huni, and M. Tagdi, “Tolerance and efficacy of interferon-alpha in hemodialysis patients in Tripoli,” Saudi Journal of Kidney Diseases and Transplantation, vol. 17, no. 3, pp. 338–343, 2006. View at Google Scholar · View at Scopus
  79. I. Grgurević, A. Vince, M. Buljevac et al., “Efficacy of interferon-α in the treatment of chronic hepatitis C in dialysis patients: two therapeutic protocols compared,” Nephron, vol. 103, no. 1, pp. c8–c11, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. W. C. Chow, S. L. Tien, C. K. Tan, H. F. Lui, A. Vathsala, and H. S. Ng, “Treatment of chronic hepatitis C in patients with end-stage renal disease and hemophilia—the Singapore experience,” Intervirology, vol. 49, no. 1-2, pp. 107–111, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. F. Fabrizi, G. Dulai, V. Dixit, S. Bunnapradist, and P. Martin, “Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients,” Alimentary Pharmacology and Therapeutics, vol. 18, no. 11-12, pp. 1071–1081, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. I. Sporea, A. Popescu, R. Şirli et al., “Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis,” World Journal of Gastroenterology, vol. 12, no. 26, pp. 4191–4194, 2006. View at Google Scholar · View at Scopus
  83. M. W. Russo, R. Ghalib, S. Sigal, and V. Joshi, “Randomized trial of pegylated interferon α-2b monotherapy in haemodialysis patients with chronic hepatitis C,” Nephrology Dialysis Transplantation, vol. 21, no. 2, pp. 437–443, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Covic, I. D. Maftei, N. G. I. Mardare et al., “Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit,” Journal of Nephrology, vol. 19, no. 6, pp. 794–801, 2006. View at Google Scholar · View at Scopus
  85. O. F. Kokoglu, H. Uçmak, S. Hosoglu et al., “Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C,” Journal of Gastroenterology and Hepatology, vol. 21, no. 3, pp. 575–580, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. K. Alsaran, A. Sabry, and N. Shaheen, “Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience,” International Urology and Nephrology, vol. 43, no. 3, pp. 865–873, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. F. Fabrizi, V. Dixit, P. Messa, and P. Martin, “Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials,” Journal of Viral Hepatitis, vol. 15, no. 2, pp. 79–88, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Bruchfeld, K. Lindahl, O. Reichard, T. Carlsson, and R. Schvarcz, “Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients,” Journal of Viral Hepatitis, vol. 13, no. 5, pp. 316–321, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. M. Rendina, A. Schena, N. M. Castellaneta et al., “The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant,” Journal of Hepatology, vol. 46, no. 5, pp. 768–774, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. R. van Leusen, R. P. R. Adang, R. A. De Vries et al., “Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C,” Nephrology Dialysis Transplantation, vol. 23, no. 2, pp. 721–725, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. D. Carriero, F. Fabrizi, A. J. Uriel, J. Park, P. Martin, and D. T. Dieterich, “Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin,” International Journal of Artificial Organs, vol. 31, no. 4, pp. 295–302, 2008. View at Google Scholar · View at Scopus
  92. C. H. Liu, C. C. Liang, C. J. Liu et al., “Pegylated interferon α-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy,” Gut, vol. 58, no. 2, pp. 314–316, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. W. Hakim, S. Sheikh, I. Inayat et al., “HCV response in patients with end stage renal disease treated with combination pegylated interferon α-2a and ribavirin,” Journal of Clinical Gastroenterology, vol. 43, no. 5, pp. 477–481, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. K. Al-Saran, A. Sabry, N. Shaheen, and A. Yehia, “Treatment of a common problem in hemodialysis patients: is the juice worth the squeeze?” Saudi Journal of Kidney Diseases and Transplantation, vol. 20, no. 5, pp. 876–882, 2009. View at Google Scholar · View at Scopus
  95. A. Giguere, A. Anas, T. Nasser et al., “Treatment of hepatitis C virus infection in patients on maintenance hemodialysis: a single United Arab Emirates center experience,” European Journal of Internal Medicine, vol. 22, no. 6, pp. 582–586, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. P. Deltenre, C. Moreno, A. Tran et al., “Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy,” Alimentary Pharmacology and Therapeutics, vol. 34, no. 4, pp. 454–461, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Bruchfeld, K. Lindahl, R. Schvarcz, and L. Ståhle, “Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis,” Therapeutic Drug Monitoring, vol. 24, no. 6, pp. 701–708, 2002. View at Publisher · View at Google Scholar · View at Scopus
  98. D. B. Strader, T. Wright, D. L. Thomas, and L. B. Seeff, “Diagnosis, management, and treatment of hepatitis C,” Hepatology, vol. 39, no. 4, pp. 1147–1171, 2004. View at Publisher · View at Google Scholar · View at Scopus
  99. P. Martin, D. Carter, F. Fabrizi et al., “Histopathological features of hepatitis C in renal transplant candidates,” Transplantation, vol. 69, no. 7, pp. 1479–1484, 2000. View at Google Scholar · View at Scopus
  100. L. Rostaing, E. Chatelut, J. L. Payen et al., “Pharmacokinetics of αIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications,” Journal of the American Society of Nephrology, vol. 9, no. 12, pp. 2344–2348, 1998. View at Google Scholar · View at Scopus
  101. S. Badalamenti, A. Catania, G. Lunghi et al., “Changes in viremia and circulating interferon-α during hemodialysis in hepatitis C virus-positive patients: only coincidental phenomena?” American Journal of Kidney Diseases, vol. 42, no. 1, pp. 143–150, 2003. View at Publisher · View at Google Scholar · View at Scopus
  102. T. Rampino, E. Arbustini, M. Gregorini et al., “Hemodialysis prevents liver disease caused by hepatitis C virus: role of hepatocyte growth factor,” Kidney International, vol. 56, no. 6, pp. 2286–2291, 1999. View at Publisher · View at Google Scholar · View at Scopus
  103. T. Poynard, P. Marcellin, S. S. Lee et al., “Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus,” The Lancet, vol. 352, no. 9138, pp. 1426–1432, 1998. View at Publisher · View at Google Scholar · View at Scopus
  104. G. L. Davis, L. A. Balart, E. R. Schiff et al., “Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial,” The New England Journal of Medicine, vol. 321, no. 22, pp. 1501–1506, 1989. View at Google Scholar · View at Scopus
  105. T. Thévenot, C. Regimbeau, V. Ratziu, V. Leroy, P. Opolon, and T. Poynard, “Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update,” Journal of Viral Hepatitis, vol. 8, no. 1, pp. 48–62, 2001. View at Publisher · View at Google Scholar · View at Scopus
  106. F. Fabrizi, V. Dixit, P. Martin, and P. Messa, “Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials,” Journal of Viral Hepatitis, vol. 18, no. 7, pp. e263–e269, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. J. G. McHutchison, G. T. Everson, S. C. Gordon et al., “Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection,” The New England Journal of Medicine, vol. 360, no. 18, pp. 1827–1838, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. C. Hézode, N. Forestier, G. Dusheiko et al., “Telaprevir and peginterferon with or without ribavirin for chronic HCV infection,” The New England Journal of Medicine, vol. 360, no. 18, pp. 1839–1850, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. G. Ghany, D. Nelson, D. Strader, D. Thomas, and L. Seeff, “An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases,” Hepatology, vol. 54, pp. 1433–1434, 2011. View at Google Scholar
  110. S. Pol, A. Vallet-Pichard, M. Corouge, and V. Mallet, “Hepatitis C: epidemiology, diagnosis, natural history and therapy,” Contributions to Nephrology, vol. 176, pp. 1–9, 2012. View at Google Scholar